Amicus Therapeutics, Inc. (FOLD) Reviewed By Analysts

Barsaba Taglieri
Luglio 12, 2017

The market experts are predicting a 52.09% rally, based on the high target price ($16) for WisdomTree Investments, Inc. shares that is likely to be hit in the 52 weeks.

Press coverage about Amicus Therapeutics (NASDAQ:FOLD) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Leerink Swann restated an "outperform" rating and set a $15.00 price objective on shares of Amicus Therapeutics in a report on Thursday, March 30th.

Amicus has an analyst consensus of Strong Buy, with a price target consensus of $12.50. Amicus Therapeutics has a 1-year low of $4.41 and a 1-year high of $13.28. Point72 Asset Management L.P. bought a new stake in shares of Amicus Therapeutics during the first quarter worth about $21,394,000. $14's average target is 8.36% above currents $12.92 stock price.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, May 9th. Credit Suisse AG raised its stake in shares of Amicus Therapeutics by 58.9% in the first quarter. It is negative, as 27 investors sold Amicus Therapeutics, Inc. shares while 32 reduced holdings.

Last time, the company failed Wall Street by reporting EPS of $-0.39, smashing the consensus of $-0.36 per share. Most investors instead focused on individual companies and their news, and Halcon Resources (NYSE: HK), Amicus Therapeutics (NASDAQ: FOLD), and Rent-A-Center (NASDAQ: RCII) were among the best performers on the day.

Amicus Therapeutics, Inc. notes that there are roughly 3,000 people in the United States that suffer from Fabry disease.

FOLD's fiscal year ends Dec 31, 2016 and the most recent quarter started on Mar 31, 2017.

In the last reported quarter, Amicus Therapeutics reported its Actual EPS (earnings per share) of $-0.39/share where most of the analysts working on this stock were estimating the EPS to be $-0.36/share. Before the market open, the tiny biotech announced that the US Food and Drug Administration (FDA) has cleared the way for the company to submit a New Drug Application (NDA) for its Fabry disease drug. The firm had revenue of $4.20 million during the quarter, compared to analyst estimates of $4.16 million. Now that the FDA has given the green light, Amicus plans on sending in its NDA sometime during the fourth quarter of this year. The company now has a consensus rating of "Buy" and an average price target of $11.46. If you are accessing this report on another site, it was stolen and republished in violation of United States & global copyright & trademark law. The legal version of this story can be read at https://www.thestockobserver.com/2017/07/11/amicus-therapeutics-inc-fold-earns-buy-rating-from-cowen-and-company.html. The transaction was disclosed in a filing with the SEC, which is available through this link. Total Debt/Equity is 50.47 and the Book value per Share is 2.18.

Amicus Therapeutics, Inc.is a biopharmaceutical company. Following the sale, the insider now owns 474,438 shares in the company, valued at approximately $3,795,504. The stock was sold at an average price of $10.00, for a total transaction of $300,000.00. Also, insider Hung Do sold 29,914 shares of the company's stock in a transaction dated Friday, May 19th. Following the completion of the sale, the insider now owns 64,184 shares in the company, valued at $641,840. The disclosure for this sale can be found here. The Firm is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases.

Altre relazioni OverNewsmagazine

Discuti questo articolo

SEGUI I NOSTRI GIORNALE